focus -WSS

focus

author：hotspot 2025-09-06 05:03:02 - browse：33564

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Pharma companies must ensure equitable access to obesity drugs

WSS

After Sarepta trial failure, Duchenne families brace for more debate

New report analyzes digital physical therapy solutions' effectiveness

ALS patient reclaims some autonomy thanks to wearable 'robot'

Moderna says combo Covid

Pharma companies must ensure equitable access to obesity drugs

Explaining an after

entertainment

focus

focus

Medical leaders decry Supreme Court decision on affirmative action

Coercive sterilizations revealed by STAT prompt outrage

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: ESMO highlights & Roivant's big deal

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Moderna says combo Covid

Guidelines to prevent youth baseball injuries need more muscle

Medicare must police algorithms in Medicare Advantage, Dems say

Psychedelics group wrestles with new pharma identity

My daughter's legacy lives on through her writing, phage therapy

Wikipedia

Medicare must police algorithms in Medicare Advantage, Dems say

Gene therapy’s promise and the high cost of hope

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Teladoc has a new CEO, but challenges remain the same

Teladoc has a new CEO, but challenges remain the same

Gene therapy’s promise and the high cost of hope

entertainment

focus

Wikipedia

leisure time